{
  "ticker": "NSB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973162",
  "id": "02973162",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250728",
  "time": "0919",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m69mxpx63l74.pdf",
  "summary": "- **CEO Appointment**: Nathan Smith appointed as CEO effective 28 July 2025, bringing expertise in cell/gene therapy, GMP manufacturing, and commercialization.  \n- **Strategic Focus**: Key focus on scaling StemSmart\u2122 technology for Crohn\u2019s disease and advancing MSC-based therapy toward clinical trials.  \n- **Equity Incentives**:  \n  - 1.5m options at $0.15, 1.5m at $0.25 (3-year expiry, 12-month vesting).  \n  - 1.5m performance rights tied to securing a \u2265$150M USD partnership.  \n\n*No material trading or capital markets impacts identified (no capital raising, financials, or material pipeline milestones disclosed).*",
  "usage": {
    "prompt_tokens": 1564,
    "completion_tokens": 152,
    "total_tokens": 1716,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T23:38:11.831234"
}